BioAtla shares surge 14.81% premarket after $40M SPV deal to advance cancer drug with GATC Health.

BioAtla Inc. (NASDAQ:BCAB) surged 14.81% in premarket trading following a regulatory update on its clinical development plan for ozuriftamab vedotin in oropharyngeal squamous cell carcinoma (OPSCC) after a productive Type B meeting with the FDA. The announcement, reported 1 hour prior to the price movement, highlighted positive feedback from the FDA, reinforcing confidence in the drug’s progression. This development aligns with the company’s focus on advancing its oncology pipeline, particularly in HPV-associated cancers, and follows earlier news of a $40 million SPV partnership with GATC Health to accelerate drug development. The premarket rally reflects optimism about regulatory clarity and potential milestones in its key therapeutic programs.